生产企业：PersonGen BioTherapeutics (Suzhou) Co., Ltd.
PA3-17 is an investigational CD7-targeted autologous CAR-T cell therapy developed by PersonGen BioTherapeutics for the treatment of relapsed or refractory T-lymphoblastic leukemia/lymphoma (R/R T-ALL/LBL). It is the world's first CD7-targeted autologous CAR-T product to enter clinical trials, utilizing a non-gene-editing dual-lentivirus strategy to avoid CD7-mediated fratricide. Phase I data showed 85% ORR and 95% MRD-negative CR. A pivotal Phase II trial began dosing in 2025.
PA3-17 is an investigational CD7-targeted autologous CAR-T cell therapy developed by PersonGen BioTherapeutics for the treatment of relapsed or refractory T-lymphoblastic leukemia/lymphoma (R/R T-ALL/LBL). It is the world's first CD7-targeted autologous CAR-T product to enter clinical trials, utilizing a non-gene-editing dual-lentivirus strategy to avoid CD7-mediated fratricide. Phase I data showed 85% ORR and 95% MRD-negative CR. A pivotal Phase II trial began dosing in 2025.
Relapsed or refractory T-lymphoblastic leukemia/lymphoma (R/R T-ALL/LBL). In Phase I registration trials, PA3-17 achieved an objective response rate (ORR) of 85% and a minimal residual disease (MRD)-negative complete remission rate of 95%. Traditional chemotherapy for this patient population yields a 5-year survival rate of less than 20% and a long-term survival rate below 10% after relapse.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
